Read More...June 15, 2012
The American College of Neurocognitive Medicine's (ACNM) mission is to advance the knowledge and practice of physicians and other select clinicians who diagnose and treat persons who are suffering from neuropsychiatric and neurocognitive impairments resulting from traumatic brain injury, dementia, post-stroke cognitive deficits, cognitive and behavioral impairments secondary to developmental disabilities and/or genetic syndromes or disorders, and neurocognitive impairments that occur in auto-immune or neuropsychiatric diseases such as Multiple Sclerosis, Gilles de la Tourette's Syndrome, and Wilson's Disease.
The ACNM supports training and research initiatives in the following principal areas:
• To advance diagnostic skill in patients with brain dysfunction via specialized neuropsychiatric testing to include specialized neurological examination, specialized neurocognitive testing, quantitative electrophysiological testing, and neuroimaging.
• Supporting and advancing broader knowledge in the field through core literature, proprietary educational material, conferences, and by funding eminent speakers and academic engagements.
• Supporting advanced practices in neuropsychopharmacology, with special emphasis on psychotropic neuroplasticity, psychostimulants, cholinesterase inhibitors, NMDA receptor antagonisists, anticonvulsants, typical and atypical antipsychotics, antidepressants, and emerging neuropharmacologic agents.
The ACNM also supports advance knowledge of scientifically-based Complementary and Alternative Medicine agents ('CAM'), as well as novel and on-going research therein.
.jpg)